Literature DB >> 14527303

Molecular pathogenesis of pancreatic cancer.

Donna E Hansel1, Scott E Kern, Ralph H Hruban.   

Abstract

Pancreatic cancer is an almost universally fatal disease, with a five-year survival rate of 5%. Research into both sporadic and inherited forms of pancreatic cancer has yielded tremendous advances in the understanding of this disease at the molecular level. Elucidating genetic alterations in pancreatic cancer has identified various abnormalities ranging from gross chromosomal abnormalities to point mutations, many of which influence the development and progression of pancreatic cancer. Identifying precursor lesions within pancreatic ducts has led to the formulation of a progression model of pancreatic cancer and subsequent identification of early- and late-stage changes leading to invasive cancer. Ultimately, understanding the genetic events underlying the development of pancreatic cancer may serve as a useful adjunct in the screening and treatment of patients suffering from, or at risk for, pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527303     DOI: 10.1146/annurev.genom.4.070802.110341

Source DB:  PubMed          Journal:  Annu Rev Genomics Hum Genet        ISSN: 1527-8204            Impact factor:   8.929


  61 in total

1.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Changes in connexin43 expression and localization during pancreatic cancer progression.

Authors:  Joell L Solan; Sunil R Hingorani; Paul D Lampe
Journal:  J Membr Biol       Date:  2012-06-23       Impact factor: 1.843

3.  Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.

Authors:  Nabeel Bardeesy; Kuang-Hung Cheng; Justin H Berger; Gerald C Chu; Jessica Pahler; Peter Olson; Aram F Hezel; James Horner; Gregory Y Lauwers; Douglas Hanahan; Ronald A DePinho
Journal:  Genes Dev       Date:  2006-11-15       Impact factor: 11.361

4.  Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.

Authors:  Sally E Dowen; Tatjana Crnogorac-Jurcevic; Rathi Gangeswaran; Mikkel Hansen; Jyrki J Eloranta; Vipul Bhakta; Teresa A Brentnall; Jutta Lüttges; Gunther Klöppel; Nick R Lemoine
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

Review 5.  [Pathogenesis of the ductal pancreatic adenocarcinoma: implications for future therapies?].

Authors:  G Schneider; R M Schmid
Journal:  Internist (Berl)       Date:  2005-02       Impact factor: 0.743

6.  Restoration of Smad4 in BxPC3 pancreatic cancer cells attenuates proliferation without altering angiogenesis.

Authors:  Michiya Yasutome; Jason Gunn; Murray Korc
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 7.  The pancreatic cancer genome revisited.

Authors:  Akimasa Hayashi; Jungeui Hong; Christine A Iacobuzio-Donahue
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-04       Impact factor: 46.802

8.  Genetics and pathology of pancreatic cancer.

Authors:  Jordan M Winter; Anirban Maitra; Charles J Yeo
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

9.  Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX.

Authors:  Vindhya Palagani; Mona El Khatib; Uta Kossatz; Przemyslaw Bozko; Martin R Müller; Michael P Manns; Till Krech; Nisar P Malek; Ruben R Plentz
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

10.  Association between OGG1 gene single nucleotide polymorphisms and risk of pancreatic cancer in Chinese.

Authors:  Chengli Liu; Hui Huang; Cheng Wang; Yalin Kong; Hui Zhang; Hongyi Zhang
Journal:  Med Oncol       Date:  2014-06-17       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.